Cas:251096-97-6 1-(3-(trifluoromethyl)benzenesulfonyl)proline manufacturer & supplier

We serve Chemical Name:1-(3-(trifluoromethyl)benzenesulfonyl)proline CAS:251096-97-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-(3-(trifluoromethyl)benzenesulfonyl)proline

Chemical Name:1-(3-(trifluoromethyl)benzenesulfonyl)proline
CAS.NO:251096-97-6
Synonyms:1-(3-(TRIFLUOROMETHYL)BENZENESULFONYL)PROLINE;1-[3-(trifluoromethyl)benzenesulfonyl]pyrrolidine-2-carboxylic acid;F3394-1123;1-([3-(trifluoromethyl)phenyl]sulfonyl)-2-pyrrolidinecarboxylic acid;1-[3-(trifluoromethyl)benzenesulphonyl]pyrrolidine-2-carboxylic acid
Molecular Formula:C12H12F3NO4S
Molecular Weight:323.28800
HS Code:2933990090

Physical and Chemical Properties:
Melting point:107-108ºC
Boiling point:460.6ºC at 760mmHg
Density:1.519g/cm3
Index of Refraction:1.544
PSA:83.06000
Exact Mass:323.04400
LogP:2.96180

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-(3-(TRIFLUOROMETHYL)BENZENESULFONYL)PROLINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[3-(trifluoromethyl)benzenesulphonyl]pyrrolidine-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,F3394-1123 Use and application,F3394-1123 technical grade,usp/ep/jp grade.


Related News: The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. Thioacetic acid S-(2-bromo-3-oxo-1,3-diphenyl-propyl) ester manufacturers Besides McNamara’s hire, GSK said it’s expected to name a chair for the OTC firm later this year, who will then establish the board. 3-[(9-β-D-ribofuranosyl-9H-purin-6-ylamino)-methyl]-benzamide suppliers CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells. 2-(4-chlorophenyl)-1,2-dihydro-1-methyl-3H-pyrazolo(3,4-d)thieno(3,2-b)pyridin-3-one vendor & factory.